Fig. 4: HIS-low tumors were sensitive to anti-PD1 therapy, while HIS-high tumors were resistant. | Cell Death & Disease

Fig. 4: HIS-low tumors were sensitive to anti-PD1 therapy, while HIS-high tumors were resistant.

From: High baseline levels of PD-L1 reduce the heterogeneity of immune checkpoint signature and sensitize anti-PD1 therapy in lung and colorectal cancers

Fig. 4: HIS-low tumors were sensitive to anti-PD1 therapy, while HIS-high tumors were resistant.

The growth curves and tumor growth inhibition (TGI) of MCA38-pCDH and MCA38-PD-L1 tumors treated with either IgG or an anti-PD1 antibody when tumor sizes reached 4.0–5.0 mm (A) and 7.0–8.0 mm (B) in diameter, respectively. The growth curves and TGI of LAP-pCDH and LAP-PD-L1 tumors treated with IgG or an anti-PD1 antibody when the sizes of tumors reached 3.0–4.0 mm (C) and 5.0–6.0 mm (D) in diameter, respectively. Treatments were administered intraperitoneally at the indicated dose regimes every 3 days. E Control MCA38-pCDH or MCA38-PD-L1 tumors were treated with anti-PD1 or isotype IgG antibodies when tumors reached 7.0–8.0 mm and continued every 3 days. The percentages of intratumoral CD4+ T cells, CD8+ T cells, CD4+CD25+ Tregs, CD4+CD44+CD69+ T cells, and CD8+CD44+CD69+ T cells were analyzed by flow cytometry. (F) The growth curves and weights of MCA38-PD-L1 tumors were monitored after treatment with various antibody regimes (IgG, anti-PD1, anti-CD4, anti-CD8) administered as indicated in the figure every 3 days. Treatments were initiated when tumors reached 7.0–8.0 mm in diameter. Each dot represents one individual tumor sample. Data are shown as the mean ± SEM. Significance was determined by two-way ANOVA. Data represent two (A, B, E, F) or three (C, D) independent experiments with similar results.

Back to article page